Articles from BioAegis Therapeutics
Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.
By BioAegis Therapeutics · Via GlobeNewswire · June 17, 2025
Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers
By BioAegis Therapeutics · Via GlobeNewswire · June 10, 2025
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens.
By BioAegis Therapeutics · Via GlobeNewswire · May 6, 2025
Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025.
By BioAegis Therapeutics · Via GlobeNewswire · March 18, 2025

Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.
By BioAegis Therapeutics · Via GlobeNewswire · October 17, 2024

NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its Co-founder, Steve Cordovano, will present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City on September 18 and 19.
By BioAegis Therapeutics · Via GlobeNewswire · September 12, 2024

Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.
By BioAegis Therapeutics · Via GlobeNewswire · February 27, 2024

Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.
By BioAegis Therapeutics · Via GlobeNewswire · October 16, 2023

Webinar will take place Tuesday, May 23, 2023 at 2:00 PM Eastern Time
By BioAegis Therapeutics · Via GlobeNewswire · May 10, 2023

Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes.
By BioAegis Therapeutics · Via GlobeNewswire · April 13, 2023

NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human immune regulatory protein, announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for recombinant plasma gelsolin to proceed for the treatment of acute respiratory distress syndrome (ARDS).
By BioAegis Therapeutics · Via GlobeNewswire · January 26, 2023

Company directs clinical effort of its breakthrough therapy to Acute Respiratory Distress Syndrome, for which there are no currently approved treatments.
By BioAegis Therapeutics · Via GlobeNewswire · January 6, 2023

NORTH BRUNSWICK, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory diseases based on a portfolio built around gelsolin technology, announces a new article on its novel host-directed approach.
By BioAegis Therapeutics · Via GlobeNewswire · December 5, 2022